{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:16:19Z","timestamp":1789596979914,"version":"build-2803163510"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,2,1]]},"DOI":"10.1093\/jac\/dkh516","type":"journal-article","created":{"date-parts":[[2005,1,13]],"date-time":"2005-01-13T20:18:54Z","timestamp":1105647534000},"page":"280-281","source":"Crossref","is-referenced-by-count":32,"title":["Pharmacokinetics and hepatotoxicity of lopinavir\/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients"],"prefix":"10.1093","volume":"55","author":[{"given":"F.","family":"Canta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Marrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bonora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"D'Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sciandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sinicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. G.","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,2]]},"reference":[{"key":"key\n\t\t\t\t20171013032447_R1","doi-asserted-by":"crossref","unstructured":"Sulkowski, M. S. (2004). Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clinical Infectious Diseases38, S90\u20137.","DOI":"10.1086\/381444"},{"key":"key\n\t\t\t\t20171013032447_R2","unstructured":"Da Silva, B., King, M., Cernohous, P. et al. (2004). Lopinavir\/ritonavir safety, tolerability and efficacy in hepatitis C and\/or hepatitis B-infected patients: review of clinical trials. In Program and Abstracts of the Fifteenth International AIDS Conference, Bangkok, 2004. Abstract MoPeB3285. International AIDS Society, Geneva, Switzerland. [Abstracts available online at http:\/\/www.iasociety.org\/ejias\/search.asp?]."},{"key":"key\n\t\t\t\t20171013032447_R3","doi-asserted-by":"crossref","unstructured":"Almond, L. M., Boffito, M., Hoggard, P. G. et al. (2004). The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Research and Human Retroviruses20, 716\u201322.","DOI":"10.1089\/0889222041524670"},{"key":"key\n\t\t\t\t20171013032447_R4","unstructured":"Arribas, J., Pulido, F., Peng, J. et al. (2003). Evaluation of multiple-dose pharmacokinetics of lopinavir\/ritonavir (LPV\/r) in HIV and HCV co-infected patients with mild or moderate hepatic insufficiency. In Program and Abstracts of the Ninth European AIDS Conference, Warsaw, 2003. Presentation #F2\/6. European AIDS Clinical Society, Paris, France. [Also available online at http:\/\/www.aegis.org\/conferences\/eacs2003\/]."},{"key":"key\n\t\t\t\t20171013032447_R5","unstructured":"Chihrin, S., Loutfy, M. R., Raboud, J. et al. (2004). Exposure to lopinavir\/ritonavir is a risk factor for grade 3\/4 elevation of ALT in HIV and hepatitis B (HBV) or C (HCV) coinfected patients. In Program and Abstracts of the Fifteenth International AIDS Conference, Bangkok, 2004. Abstract MoPeB3281. International AIDS Society, Geneva, Switzerland. [Abstracts available online at http:\/\/www.iasociety.org\/ejias\/search.asp?]."},{"key":"key\n\t\t\t\t20171013032447_R6","doi-asserted-by":"crossref","unstructured":"Gonzalez de Requena, D., Nunez, M., Jimenez-Nacher, I. et al. (2004). Liver toxicity of lopinavir\/ritonavir-containing regimens in HIV-infected patients with or without hepatitis C virus (HCV) co-infection. AIDS Research and Human Retroviruses20, 698\u2013700.","DOI":"10.1089\/0889222041524562"},{"key":"key\n\t\t\t\t20171013032447_R7","doi-asserted-by":"crossref","unstructured":"Sulkowski, M. S., Thomas, D. L., Chaisson, R. E. et al. (2000). Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. Journal of the American Medical Association283, 74\u201380.","DOI":"10.1001\/jama.283.1.74"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/55\/2\/280\/2544426\/dkh516.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T03:25:03Z","timestamp":1507865103000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/55\/2\/280\/856752\/Pharmacokinetics-and-hepatotoxicity-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,1]]},"references-count":7,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,2]]},"published-print":{"date-parts":[[2005,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkh516","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,2]]},"published":{"date-parts":[[2005,2,1]]}}}